stock delisting
Interpace Biosciences Receives Nasdaq Delisting Notice, Initiates Restructuring
The notice was issued due to the company's extended period of non-compliance with the minimum $2.5 million stockholder's equity requirement for continued listing.
T2 Biosystems Regains Compliance With Nasdaq Listing Requirements
In April the firm received notice that it wasn't in compliance because its common stock didn't maintain a minimum bid price of $1.00 for 30 consecutive business days.
T2 Biosystems Receives Nasdaq Warning Letter
The Lexington, Massachusetts-based company also terminated a purchase agreement and raised the amount in it may raise in a public offering of its common stock to $95.
Genetic Technologies Receives Nasdaq Delisting Notification
The company will not be allowed to submit another plan for meeting the Nasdaq's listing requirements.
Nasdaq Warns Biocept Over Listing Requirement
The firm has a 180-day grace period in which to regain compliance, by maintaining a $1.00 minimum closing bid price for at least 10 consecutive business days.